| Форма представления | Статьи в зарубежных журналах и сборниках |
| Год публикации | 2021 |
| Язык | английский |
|
Зинченко Сергей Викторович, автор
Киясов Андрей Павлович, автор
Литвинов Рустем Игоревич, автор
Ризванов Альберт Анатольевич, автор
Шарафеев Айдар Зайтунович, автор
|
| Библиографическое описание на языке оригинала |
Khalirakhmanov A.F. Pathogenesis, Diagnosis, and Treatment of Hemostatic Disorders in COVID-19 Patients/A.F. Khalirakhmanov, K.F. Idrisova, R.F. Gaifullina, S.V. Zinchenko, R. I. Litvinov, A. Z. Sharafeev, A. P. Kiyasov, A. A. Rizvanov//Acta Naturae. - 2021. - Vol.13, Is.2. - P.79-84. |
| Аннотация |
The novel coronavirus infection named COVID-19 was first detected in Wuhan, China, in December
2019, and it has been responsible for significant morbidity and mortality in scores of countries. At the time this
article was being written, the number of infected and deceased patients continued to grow worldwide. Most
patients with severe forms of the disease suffer from pneumonia and pulmonary insufficiency; in many cases, the
disease is generalized and causes multiple organ failures and a dysfunction of physiological systems. One of the
most serious and prognostically ominous complications from COVID-19 is coagulopathy, in particular, decom
-
pensated hypercoagulability with the risk of developing disseminated intravascular coagulation. In most cases,
local and diffuse macro- and microthromboses are present, a condition which causes multiple-organ failure and
thromboembolic complications. The causes and pathogenic mechanisms of coagulopathy in COVID-19 remain
largely unclear, but they are associated with systemic inflammation, including the so-called cytokine storm. De
-
spite the relatively short period of the ongoing pandemic, laboratory signs of serious hemostatic disorders have
been identified and measures for specific prevention and correction of thrombosis have been developed. This
review discusses the causes of COVID-19 coagulopathies and the associated complications, as well as possible
approaches to their early diagnosis, prevention, and treatment. |
| Ключевые слова |
coronavirus, hemostatic disorders, thrombosis, anticoagulants, cytokine storm, COVID-19 |
| Название журнала |
ACTA NATURAE
|
| URL |
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85112813553&doi=10.32607%2factanaturae.11182&partnerID=40&md5=6e2d644d842a9d146b14d7edcda9d5fe |
| Пожалуйста, используйте этот идентификатор, чтобы цитировать или ссылаться на эту карточку |
https://repository.kpfu.ru/?p_id=255770 |
| Файлы ресурса | |
|
|
Полная запись метаданных  |
| Поле DC |
Значение |
Язык |
| dc.contributor.author |
Зинченко Сергей Викторович |
ru_RU |
| dc.contributor.author |
Киясов Андрей Павлович |
ru_RU |
| dc.contributor.author |
Литвинов Рустем Игоревич |
ru_RU |
| dc.contributor.author |
Ризванов Альберт Анатольевич |
ru_RU |
| dc.contributor.author |
Шарафеев Айдар Зайтунович |
ru_RU |
| dc.date.accessioned |
2021-01-01T00:00:00Z |
ru_RU |
| dc.date.available |
2021-01-01T00:00:00Z |
ru_RU |
| dc.date.issued |
2021 |
ru_RU |
| dc.identifier.citation |
Khalirakhmanov A.F. Pathogenesis, Diagnosis, and Treatment of Hemostatic Disorders in COVID-19 Patients/A.F. Khalirakhmanov, K.F. Idrisova, R.F. Gaifullina, S.V. Zinchenko, R. I. Litvinov, A. Z. Sharafeev, A. P. Kiyasov, A. A. Rizvanov//Acta Naturae. - 2021. - Vol.13, Is.2. - P.79-84. |
ru_RU |
| dc.identifier.uri |
https://repository.kpfu.ru/?p_id=255770 |
ru_RU |
| dc.description.abstract |
ACTA NATURAE |
ru_RU |
| dc.description.abstract |
The novel coronavirus infection named COVID-19 was first detected in Wuhan, China, in December
2019, and it has been responsible for significant morbidity and mortality in scores of countries. At the time this
article was being written, the number of infected and deceased patients continued to grow worldwide. Most
patients with severe forms of the disease suffer from pneumonia and pulmonary insufficiency; in many cases, the
disease is generalized and causes multiple organ failures and a dysfunction of physiological systems. One of the
most serious and prognostically ominous complications from COVID-19 is coagulopathy, in particular, decom
-
pensated hypercoagulability with the risk of developing disseminated intravascular coagulation. In most cases,
local and diffuse macro- and microthromboses are present, a condition which causes multiple-organ failure and
thromboembolic complications. The causes and pathogenic mechanisms of coagulopathy in COVID-19 remain
largely unclear, but they are associated with systemic inflammation, including the so-called cytokine storm. De
-
spite the relatively short period of the ongoing pandemic, laboratory signs of serious hemostatic disorders have
been identified and measures for specific prevention and correction of thrombosis have been developed. This
review discusses the causes of COVID-19 coagulopathies and the associated complications, as well as possible
approaches to their early diagnosis, prevention, and treatment. |
ru_RU |
| dc.language.iso |
ru |
ru_RU |
| dc.subject |
coronavirus |
ru_RU |
| dc.subject |
hemostatic disorders |
ru_RU |
| dc.subject |
thrombosis |
ru_RU |
| dc.subject |
anticoagulants |
ru_RU |
| dc.subject |
cytokine storm |
ru_RU |
| dc.subject |
COVID-19 |
ru_RU |
| dc.title |
Pathogenesis, Diagnosis, and Treatment of Hemostatic Disorders in COVID-19 Patients |
ru_RU |
| dc.type |
Статьи в зарубежных журналах и сборниках |
ru_RU |
|
EN 
中文 
ES 
Карта сайта
